Related Experiment Video

Updated: Mar 13, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis

Seongyeong Kim1, Ahrum Min1,2, Kyung-Hun Lee1,2,3

  • 1Cancer Research Institute, Seoul National University, Seoul, Korea.

Cancer Research and Treatment
|October 15, 2016
PubMed
Abstract

Insights

KX-01, a dual inhibitor of Src and tubulin, effectively inhibited triple-negative breast cancer cell growth and migration. This novel agent demonstrated significant antitumor effects in vitro and in vivo, offering a promising therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) presents therapeutic challenges, with prior Src inhibitors showing limited clinical efficacy.
  • KX-01 is a novel dual inhibitor targeting both Src and tubulin, aiming to overcome limitations of existing therapies.

Purpose of the Study:

  • To evaluate the in vitro and in vivo activity and mechanism of the novel dual inhibitor KX-01.
  • To assess KX-01's potential against triple-negative breast cancer (TNBC).

Main Methods:

  • Antitumor effects were assessed using MTT assays in TNBC cell lines.
  • Mechanism of action investigated via wound healing, immunofluorescence, cell cycle, and molecular analyses.
  • In vivo efficacy evaluated using a MDA-MB-231 mouse xenograft model.

Main Results:

  • KX-01 inhibited TNBC cell growth and down-regulated phospho-Src and proliferative signaling.
  • Wound healing assays showed inhibition of cell migration; cell cycle analysis revealed G2/M arrest and increased aneuploidy.
  • Significant increases in multi-nucleated cells and delayed tumor growth were observed in vivo.

Conclusions:

  • KX-01 demonstrates potent inhibition of TNBC cell growth and migration.
  • The drug exerts antitumor effects by inhibiting Src signaling and inducing mitotic catastrophe.
  • KX-01 shows significant in vivo antitumor activity in a preclinical model.
Keywords:
KX-01MicrotubulesMitotic catastropheSrc kinase inhibitorTriple negative breast neoplasms

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K